Why Diabetes Is the Ideal RTM Use Case
Remote therapeutic monitoring (RTM) — introduced as a permanent billing category by CMS in 2022 — is purpose-built for the chronic disease management model that defines endocrinology practice. Unlike remote patient monitoring (RPM), which tracks physiologic data like blood pressure and weight, RTM is specifically designed for therapeutic adherence and response monitoring — the exact clinical question at the heart of diabetes management: is the patient taking their medications, using their CGM correctly, and achieving glycemic targets between quarterly office visits? The widespread adoption of continuous glucose monitors (CGMs) — primarily Dexcom G7 and Abbott FreeStyle Libre 3 — has created an unprecedented data resource for between-visit glucose pattern analysis. These devices generate 288+ glucose readings per day, time-in-range statistics, hypoglycemia alerts, and glycemic variability metrics that are clinically far superior to a quarterly HbA1c drawn at the office visit. The clinical problem has always been: who reviews this data, and how does the practice get paid for that review? RTM billing answers both questions. CPT 98975 (RTM device setup and patient education, 20+ minutes, billed once per episode) enables billing for the onboarding process. CPT 98980 covers the first 20 minutes of RTM clinical staff time per calendar month. CPT 98981 covers each additional 20 minutes. For a practice managing 80 diabetic patients in an RTM program, this represents a predictable monthly revenue stream that supplements — and in many cases exceeds — the revenue generated by quarterly office visits alone.
CGM Platforms: Dexcom G7 and FreeStyle Libre 3 in Clinical Practice
The two dominant CGM platforms used in endocrinology RTM programs — Dexcom G7 and Abbott FreeStyle Libre 3 — have distinct technical characteristics that affect both patient selection and data integration workflows. Dexcom G7 offers real-time continuous monitoring with a 10-day sensor wear period, predictive low glucose alerts, and integration with smartphone apps (Dexcom Clarity) and Apple Health. The Clarity provider platform displays standardized ambulatory glucose profile (AGP) reports that show 14-day glucose overlays, time-in-range breakdowns, and coefficient of variation — the metrics most relevant to clinical decision-making. Libre 3 uses factory-calibrated sensors with a 14-day wear period and similar AGP reporting through the LibreView provider platform. A critical difference: Libre 3 requires active scan (NFC) or passive continuous transmission depending on app version, while Dexcom G7 transmits continuously to the receiver and smartphone. For RTM purposes, both platforms support provider data sharing, enabling the clinical team to review patient CGM data without requiring the patient to upload the device at each visit. The RTM clinical review workflow using these platforms involves: (1) provider-initiated data pull from Clarity or LibreView, (2) structured review of time-in-range (TIR) using the international consensus targets (TIR >70% for most T1D and T2D patients, >50% for older/high-risk patients), (3) identification of hypoglycemia patterns (time below range <70 mg/dL should be <4%, <54 mg/dL should be <1%), and (4) documentation of clinical assessment and any medication or behavioral adjustments communicated to the patient between visits.
Glucose Pattern Analysis and Clinical Decision-Making Between Visits
The clinical value of diabetes RTM lies in the ability to identify and correct glucose patterns before they manifest as HbA1c deterioration or hypoglycemic events. Traditional quarterly office visit management — drawing an HbA1c and adjusting insulin empirically — provides a 90-day average that obscures critically important glucose patterns. A patient with an HbA1c of 7.8% may have excellent daytime control with severe nocturnal hypoglycemia that the HbA1c completely masks. Time-in-range analysis across the AGP report identifies these patterns: consistently low overnight readings from 12:00–4:00 AM suggest basal insulin is over-dosed for overnight sensitivity. Postprandial spikes at 1:00–3:00 PM suggest inadequate mealtime coverage for lunch. Weekend versus weekday glucose pattern divergence suggests behavioral contributors to glycemic variability. In an RTM model, these patterns are identified within the first month of monitoring — not at a quarterly visit — and corrective adjustments can be communicated via portal message, phone call, or telehealth visit. Insulin dose compliance monitoring is another high-value RTM function: bolus insulin omission patterns (consistently missing mealtime boluses identified by absence of meal-associated glucose excursions) can be identified and addressed with behavioral coaching. For patients on GLP-1/insulin combination therapy or basal-bolus insulin regimens, RTM data enables the clinical team to distinguish between insulin dose inadequacy and patient non-adherence — a distinction that significantly affects the appropriate clinical response. Documentation of clinical decision-making based on RTM data — specific glucose patterns identified, clinical assessment, and action taken — is required to support RTM billing and must be included in a dated clinical note or portal communication.
HbA1c Trend Tracking and Longitudinal Outcome Management
While CGM-based RTM focuses on real-time glucose patterns, HbA1c trending within the RTM framework provides the longitudinal outcome context that ties together the between-visit monitoring data. For RTM documentation purposes, each month's clinical review should include a reference to the most recent HbA1c and the directional trend: improving, stable, or worsening. A patient whose HbA1c trended from 9.2% → 8.1% → 7.4% over three quarters while enrolled in RTM has a documented outcome trajectory that supports both the clinical and billing justification for ongoing RTM engagement. HbA1c targets should be individualized: <7.0% (ADA standard) for most non-pregnant adults; <8.0% for patients with hypoglycemia unawareness, limited life expectancy, or significant comorbidities; <6.5% for selected younger patients with low hypoglycemia risk. RTM documentation should explicitly reference the individualized target and assess the patient's current status relative to it. Correlation between HbA1c and CGM metrics is an important clinical teaching point: HbA1c of 7.0% corresponds to an estimated average glucose (eAG) of approximately 154 mg/dL and a TIR of roughly 65–70% (in the absence of significant glycemic variability). Patients with high glycemic variability may have a "normal" HbA1c that masks dangerous hypoglycemia — a pattern that RTM is uniquely positioned to detect and correct. The RTM clinical note should document this correlation analysis monthly, demonstrating active clinical engagement with the monitoring data rather than passive data receipt.
Hypoglycemia Detection and Safety Monitoring
Hypoglycemia detection is one of the highest-value clinical functions of diabetes RTM and a compelling safety argument for RTM program enrollment in insulin-treated patients. Severe hypoglycemia (glucose <54 mg/dL) is associated with a 3.4-fold increased risk of major adverse cardiovascular events, falls and fractures in older patients, and — in patients with hypoglycemia unawareness — risk of loss of consciousness without warning. Traditional office-visit-based monitoring relies on patient self-report of hypoglycemic episodes, which is notoriously unreliable: patients underestimate hypoglycemia frequency by 50–70% compared to CGM-documented events. In an RTM program, hypoglycemia patterns are objectively documented. The clinical response workflow for significant hypoglycemia identified in RTM review should be tiered: mild hypoglycemia (<70 mg/dL, brief duration, no pattern) → educational reinforcement via portal message; significant hypoglycemia (<70 mg/dL, >15 min duration, or >2 events per week) → same-day nurse call, medication review, and dose adjustment; severe hypoglycemia pattern (<54 mg/dL or loss of consciousness history) → urgent provider review, potential dose reduction, and consideration of hypoglycemia unawareness evaluation. RTM platforms should generate automated alerts to clinical staff when CGM data shows glucose values below predefined thresholds, enabling same-day clinical response without waiting for the provider's scheduled monthly review. This alert-based workflow requires defined clinical protocols — who receives the alert, what action is required, and what documentation is needed — to function safely and consistently.
CPT Code Billing Requirements for Diabetes RTM
Correctly billing RTM for a diabetes practice requires understanding the specific requirements and distinctions among CPT codes 98975, 98980, and 98981. CPT 98975 — the RTM device setup and education code — is billed once per therapeutic episode (not per month) and requires 20+ minutes of clinical staff time dedicated to device setup, technical training, and patient education on the RTM program goals. This code is typically billed at the enrollment visit or within the first month and reimburses approximately $19–$25 under Medicare 2024 fee schedules. CPT 98980 is the primary monthly billing code, requiring at least 20 minutes of clinical staff time spent on RTM activities — including data review, clinical assessment, patient communication, and documentation — per calendar month. Reimbursement under Medicare 2024: approximately $48–$55. CPT 98981 is billed for each additional 20-minute increment beyond the first 20 minutes, at approximately $40–$46. A key compliance requirement: time must be tracked and documented. The clinical note or RTM encounter record must specify the date, duration, and nature of the RTM activities performed. Commercial payer coverage of RTM codes varies significantly: as of 2025, approximately 60–70% of major commercial plans cover CPT 98980/98981, with ongoing payer adoption. Practices should verify coverage for their specific payer mix before enrolling patients in RTM programs. Medicare covers RTM under Part B with no beneficiary cost-sharing, making it an excellent enrollment priority for Medicare-covered diabetic patients. Patient consent documentation is required at enrollment and must be retained in the medical record.
Revenue Math for 80 Diabetic RTM Patients
The revenue impact of a well-managed diabetes RTM program becomes compelling when calculated across a realistic patient panel. For a practice with 80 diabetic patients enrolled in RTM, the monthly revenue calculation proceeds as follows: If each patient generates a minimum of 20 minutes of RTM clinical time per month (the CPT 98980 threshold), the monthly revenue is 80 patients × $50 (blended Medicare/commercial rate) = $4,000/month. In practice, higher-complexity patients — those on insulin with poorly controlled glucose, frequent hypoglycemia, or active medication titration — routinely generate 40+ minutes of RTM time per month, enabling billing of CPT 98981 in addition to 98980. If 40% of the panel (32 patients) bill the additional 98981 code at $43/month, this adds $1,376/month. Total monthly RTM revenue for 80 patients: approximately $5,376/month, or $64,500/year. This assumes the RTM program is managed by a non-physician clinical staff member (diabetes educator, registered nurse, or certified medical assistant with provider supervision) — a staffing model that meets CPT requirements and maintains cost efficiency. The net revenue per patient per year — approximately $800 after accounting for staff time costs — compares favorably to the revenue from quarterly office visits ($150–$250 per visit × 4 visits = $600–$1,000/year) and dramatically expands the clinical touchpoints available for each patient. Practices that combine RTM with telehealth visit billing — using RTM data as the foundation for a brief telehealth check-in every 2–3 months — further increase revenue per patient while improving clinical outcomes through more frequent provider-patient contact.
Building and Scaling a Diabetes RTM Program
Implementing a sustainable diabetes RTM program requires four operational components: patient enrollment protocols, clinical monitoring workflows, billing and documentation systems, and outcome tracking. Patient enrollment begins with identifying the right candidates: insulin-treated type 1 and type 2 diabetes patients, those with recent HbA1c >8.0%, patients with hypoglycemia unawareness, or those transitioning to a new medication regimen are the highest-value RTM candidates. Enrollment conversations should clearly explain the program's clinical value — more personalized glucose management between visits — and obtain documented informed consent. The monthly monitoring workflow should be assigned to a dedicated clinical staff member (ideally a certified diabetes care and education specialist, CDCES) who pulls CGM data from Clarity or LibreView for each enrolled patient, completes a structured review template (TIR, hypoglycemia events, trend analysis, medication adherence indicators), generates a clinical note, and communicates findings and any recommendations to the patient via portal message. Supervisor physician review and co-signature requirements should be clarified in the practice's RTM program policy, as they affect both billing compliance and workflow design. Billing workflow integration must ensure that monthly RTM time is tracked at the point of documentation — not reconstructed retrospectively — and that the billing team is coded appropriately before month-end. Practices that implement RTM without dedicated billing workflow support see claim submission delays and revenue leakage of 15–25%. clinIQ's RTM module provides automated time tracking, structured documentation templates, integrated CGM data review dashboards, and automated claim generation — enabling endocrinology practices to scale a diabetes RTM program to 100+ patients with a single CDCES FTE.
clinIQ for Endocrinology
clinIQ's RTM module automates CGM data review, time tracking, and claim generation so your endocrinology team can scale diabetes monitoring without added staff.
Learn More